Patents by Inventor Holly Prentice

Holly Prentice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210246477
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: September 25, 2020
    Publication date: August 12, 2021
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 10584365
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 10, 2020
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventor: Holly Prentice
  • Patent number: 10144944
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 4, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Publication number: 20180187230
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: January 29, 2018
    Publication date: July 5, 2018
    Inventor: Holly Prentice
  • Patent number: 9926583
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 27, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 9914951
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 13, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Publication number: 20170233782
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 17, 2017
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • Publication number: 20170226553
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Application
    Filed: April 25, 2017
    Publication date: August 10, 2017
    Inventor: Holly Prentice
  • Publication number: 20170211114
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Application
    Filed: October 5, 2016
    Publication date: July 27, 2017
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 9677105
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • Patent number: 9663810
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: May 30, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Publication number: 20160376624
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 9487810
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: November 8, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 9475858
    Abstract: A method for producing recombinant polypeptides, including antibodies, having targeted levels of carboxyl terminal (C-terminal) lysine or arginine residues is presented. The method involves culturing cells expressing said polypeptides in cell culture medium having sufficient levels of lysine, arginine, and/or agents that change intracellular pH. Culturing the cells under such conditions does not affect cell growth, cell viability, or titer.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: October 25, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Publication number: 20160068881
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Inventor: Holly Prentice
  • Patent number: 9217168
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 22, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Publication number: 20150240281
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Application
    Filed: December 31, 2014
    Publication date: August 27, 2015
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 8956830
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 8852889
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 7, 2014
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Publication number: 20140274911
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani